Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

LONDON--(BUSINESS WIRE)--Come chill with us! This week is Diabetes Awareness Week and DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (rt-CGM) for people with diabetes, is honouring the theme of ‘celebrating you' with its ‘No Pricks Parlour', a pop-up ice cream van at London's South Bank. Open tomorrow, Tuesday 14 June, for one day only, everyone is invited to enjoy free ice cream along with the opportunity to learn about the importance of access to fing

Come Chill at Dexcom's ‘No Pricks Parlour' With Ed Gamble for Diabetes Awareness Week, Celebrating You!

Tandem Diabetes Care

These diabetes specialists are down but not out.

2 Beaten-Down Stocks With 80% to 113% Upside, According to Wall Street

Alphabet

Both of these stocks are down by more than 19% this year.

Will a Stock Split Help Rally These 2 Underperforming Nasdaq Stocks?

Target

Under Armour

Things are dramatically different than they were just a year ago for these companies.

Is It Time to Buy the S&P 500's 3 Worst-Performing May Stocks?

DexCom's (DXCM) G6 CGM System gets public coverage through Prince Edward Island's Diabetes Glucose Sensor Program, which can aid in effective diabetes management.

DexCom (DXCM) to Boost Diabetes Management With New Coverage

NVIDIA

You can buy and forget about these stocks.

2 of the Nasdaq's Best Long-Term Buys Right Now

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--DEXCOM TO SHOWCASE EXPANDED CGM PORTFOLIO AND INDUSTRY-LEADING CONNECTIVITY AT 82ND SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION

Dexcom to Showcase Expanded CGM Portfolio and Industry-leading Connectivity at 82nd Scientific Sessions of the American Diabetes Association

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), announced today that people with type 1 and type 2 diabetes age two and over on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System through Prince Edward Island's Diabetes Glucose Sensor Program. Prince Edward Island joins British Columbia, Alberta, Saskatchew

Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes

The company confirmed that it isn't in merger discussions with Insulet.

Why DexCom Stock Is Jumping Today

Insulet

Shares of DexCom Inc. DXCM, +5.35% surged 8.1% to pace the S&P 500's SPX, -0.37% premarket gainers, after the diabetes care company said it was not currently in "active discussions" regarding a merger. The stock has been dragged down over the past week, closing at a two-year low on Thursday, after Bloomberg reported that DexCom was in talks to buy Insulet Corp. PODD, -10.93% , a maker of insulin-infusion systems.

DexCom stock leads S&P 500's premarket gainers after denying merger talks, and Insulet stock drops

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today issued the following statement in response to recent media and market speculation: “Like many companies, Dexcom's Board and management team regularly review opportunities to enhance stockholder value and create benefits for customers, including through mergers and acquisitions. It is generally our policy not to comment on rumors or speculation, however, in light of recent sustained media and market speculation as well as the upcoming

Dexcom Issues Statement on Recent Market Speculation

We believe that this gap in the valuation of these two companies does not make sense, given that DexCom has demonstrated better revenue growth and profitability than Insulet.

What Makes DexCom Stock A Better Pick Over This Insulin Pump Maker?

Whispers of an acquisition aren't being well received by already nervous shareholders, who may be questioning the timing as well as the potential of such a deal.

Why DexCom Is Down More Than 11% on Tuesday

Insulet (PODD) stock is heading higher on Tuesday as investors react to reports that DexCom (DXCM) is considering acquiring the company. The post PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition appeared first on InvestorPlace.

PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition

Shares of Insulet Corp. PODD, +2.08% gained 9.9% in premarket trading on Tuesday, the day after Bloomberg reported that the company is in talks to be acquired by Dexcom Inc. DXCM, +0.84% , citing anonymous sources. Dexcom's stock was down 7.1% before the market opened on Tuesday.

Insulet's stock is up on Bloomberg report that it may be acquired by Dexcom

A potential deal could be announced in coming weeks, according to a Bloomberg report.

Insulet Stock Rises on Report of Dexcom Acquisition Talks

McDonald's

Pinterest

Don't let a little bit of weakness right now distract you from bigger-picture prizes.

3 Surefire Investments You'll Thank Yourself for Later

Despite a decline in bottom line, DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth and solid new customer additions.

DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates

The diabetes market is full of growth potential.

Is DexCom Stock a Buy Now?

DexCom, Inc. (NASDAQ:DXCM ) Q1 2022 Earnings Conference Call April 28, 2022 5:30 PM ET Company Participants Sean Christensen - Investor Relations Kevin Sayer - Chairman, President and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Jeff Johnson - Baird Danielle Antalffy - SVB Leerink Robbie Marcus - JPMorgan Jayson Bedford - Raymond James Matthew O'Brien - Piper Sandler Joanne Wuensch - Citi Mathew Blackman - Stifel Larry Biegelsen - Wells Fargo Marie Thibault - BTIG Travis Steed - Bank of America Steven Lichtman - Oppenheimer Margaret Kaczor - William Blair Frank Pinal - Jefferies Operator My name is Michele and I will be the operator for today's conference. [Operator Instructions] As a reminder, today's conference is being recorded.

DexCom, Inc. (DXCM) CEO Kevin Sayer on Q1 2022 Results - Earnings Call Transcript

DexCom (DXCM) delivered earnings and revenue surprises of -36% and 1.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Misses Q1 Earnings Estimates

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. The conference call will now start at 5:30 p.m. (Eastern Time). The link to the webcast will be available on the DexCom, Inc. investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (866) 374-5140 (US/Canada) or (404) 400-0571 (International) and use the

Dexcom Updates First Quarter 2022 Conference Call for April 28, 2022 at 5:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports First Quarter 2022 Financial Results

Dexcom Reports First Quarter 2022 Financial Results

DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for DexCom (DXCM) This Earnings Season?

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase for the first time its new global portfolio of real-time continuous glucose monitoring (CGM) systems at the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30, 2022 in Barcelona. The expanded portfolio includes Dexcom ONE, Dexcom G6 and the upcoming Dexcom G7, a range of exceptionally

News for DexCom Stock (DXCM)